What rights do children have when they are in hospital?
A whistlestop tour of seven of the key rights children have while they are in hospital, including those that are important for children with cancer, and see how these are respected.
New initiative supports young cancer patients with additional needs
Children with cancer who also have learning difficulties and autism often have additional needs when it comes to their care. Jeanette Hawkins, CCLG’s Chief Nurse, tells us more about a project aiming to improve support for this group of patients.
60 seconds with Pritesh Patel
Pritesh Patel, Senior Specialist Pharmacist in Paediatric Cancer at Great Ormond Street Hospital for Children and CCLG member
Molecular radiotherapy for children’s cancers
Molecular radiotherapy (MRT) is an evolving form of children’s cancer treatment. Dr Mark Gaze, Caroline Elmagrahi and Georgia Azzopardi, of University College London Hospitals NHS Foundation Trust, tell us more about what it is and what work is being done to develop its usage.
Harnessing artificial intelligence to identify new drug combinations
Artificial intelligence (AI) has helped scientists propose a promising new drug combination for DIPG brain tumours. Prof Chris Jones, Director of the Brain Tumour Research Centre of Excellence at the Institute of Cancer Research (ICR), and Dr Fernando Carceller, Paediatric Neuro-Oncology Consultant at The Royal Marsden Hospital, tell us more.
Ask the Expert: Caroline Brown
Caroline Brown, Lead Complementary Therapist for Paediatrics, Teenagers and Young Adults at The Royal Marsden Hospital
How is ambulatory care improving young people’s experiences of treatment?
Dr Alison Finch is a nurse and researcher from University College London Hospitals NHS Foundation Trust (UCLH). She explains how ambulatory care is positively impacting young people’s experiences of treatment and how a CCLG Special Interest Group has been formed to develop this care nationally.
Therapeutic drug monitoring: A novel approach to improving treatment
Gareth Veal, Professor of Cancer Pharmacology at the Newcastle University Cancer Centre, leads a team helping doctors to personalise treatments through an innovative process called ‘therapeutic drug monitoring’. Here, he tells us more about his work.
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer